Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of pyrimidine small molecule compound and its application

A small molecular compound and compound technology, applied in the field of biomedicine, can solve the problems of high toxicity and side effects, poor kinase inhibitory activity, etc., and achieve high inhibitory activity, good anti-osteosarcoma effect, and relieve wet macular degeneration or uveitis.

Active Publication Date: 2022-07-22
WENZHOU MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Currently reported selective inhibitors targeting PDGFRs include imatinib, CP-673451, etc. These inhibitors usually have many defects such as poor kinase inhibitory activity, large toxic side effects caused by multi-target inhibition, and easy drug resistance.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of pyrimidine small molecule compound and its application
  • A kind of pyrimidine small molecule compound and its application
  • A kind of pyrimidine small molecule compound and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1: Chemical synthesis of compounds 3a-3i

[0028] The synthetic route is as follows:

[0029]

[0030] The general process is as follows:

[0031] The nucleophilic substitution reaction with 6-aminoindazole takes 1a-1i as raw material to generate intermediate 2a-2i. Then 4-(4-methylpiperazine)aniline undergoes a nucleophilic substitution reaction with the obtained intermediate 2a-i to generate the final product 3a-3i.

[0032] Taking the synthesis of compound 3a as an example, the specific process is as follows:

[0033] 2,4-Dichloro-5-fluoropyrimidine (333.94 mg, 2 mmol) and N,N-diisopropylethylamine (DIPEA) (516.96 mg, 4 mmol) were dissolved in DMF (4 mL) and cooled to 0 °C . To the mixture was added 6-aminoindazole (266.3 mg, 2 mmol) in DMF (2 mL) dropwise. The reaction mixture was stirred at 0°C for about 1 hour. Next, the ice bath was removed, the reaction mixture was stirred at room temperature, and the reaction was monitored by TLC, the resulting...

Embodiment 2

[0071] Example 2: Chemical synthesis of compounds 5a-5j

[0072] The synthetic route is as follows:

[0073]

[0074] The general process is as follows:

[0075] Nucleophilic substitution of 2,4-dichloro-5-methylpyrimidine (1d) with various substituted amines gave intermediates 4a-4j. Then 4-(4-methylpiperazine)aniline undergoes a nucleophilic substitution reaction with the resulting intermediates 4a-4j to generate final products 5a-5j.

[0076] Taking the synthesis of compound 5a as an example, the specific process is as follows:

[0077] N,N-Diisopropylethylamine (DIPEA) (516.96 mg, 4 mmol) was dissolved in DMF (4 mL) and cooled to 0 °C. To the mixture was added 5-aminoindole (264.3 mg, 2 mmol) in DMF (2 mL) dropwise. The reaction mixture was stirred at 0°C for about 1 hour. Next, the ice bath was removed, the reaction mixture was stirred at room temperature, and the reaction was monitored by TLC. After the reaction was completed, the resulting mixture was extracted...

Embodiment 3

[0123] Example 3: Chemical synthesis of compounds 6a-6m

[0124] The synthetic routes of compounds 6a-6m are as follows:

[0125]

[0126] The general synthetic route is as follows:

[0127] 2,4-Dichloro-5-methylpyrimidine (1d) reacts with 6-aminoindazole to produce intermediate 2d, which undergoes nucleophilic substitution with various substituted amines to generate final products 6a-6m.

[0128] Taking the synthesis of compound 6a as an example, the specific synthesis is as follows:

[0129] Compound 2d was prepared according to Example 1. Compound 2d (259.7 mg, 1 mmol) and 4-(4-methylpiperazine)aniline (191.27 mg, 1 mmol) were dissolved in 4 ml of methanol, and TFA (148.56 μL, 2 mmol) was added. , warmed to 80 °C, and monitored the reaction by TLC. After the reaction was completed, it was cooled to room temperature, the resulting mixture was adjusted to neutral pH with saturated sodium bicarbonate, extracted with ethyl acetate (3×25 mL), washed with saturated brine, w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pyrimidine type small molecule compound and its citation. The pyrimidine type small molecule compound has high inhibitory activity on PDGFRα and PDGFRβ kinases, but weaker inhibitory activity on other kinases, so it has high selectivity and can As a potential antineoplastic or alleviating ophthalmic disease wet macular degeneration or uveitis drug.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a pyrimidine type small molecule compound and a preparation method and application thereof. Background technique [0002] Platelet-derived growth factor receptors (PDGFRs) share two isoforms, PDGFRα and PDGFRβ, which play important roles in the growth, development, angiogenesis and tissue wound repair of organisms. Under normal physiological conditions, except during development and tissue wound repair, the PDGFRs signaling pathway is generally in a quiescent state in adults. PDGFRs overexpression, gene mutation and gene rearrangement can lead to abnormal activation of PDGFRs-mediated signaling pathways and lead to a series of diseases such as fibrotic diseases, tumors and various ophthalmic diseases such as wet macular degeneration (AMD) and uveitis Therefore, PDGFRs have become important drug targets for the treatment of these diseases. [0003] Currently reported selec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D403/12C07D495/04C07D401/12C07D239/48C07D401/14A61P35/00A61P27/02
CPCC07D403/12C07D495/04C07D401/12C07D239/48C07D401/14A61P35/00A61P27/02
Inventor 李校堃刘志国林丽郑小辉钱建畅
Owner WENZHOU MEDICAL UNIV